All Stories: non-small cell lung cancer

CHICAGO: A Novartis trial of two drugs against an aggressive lung cancer bodes well for broadening their use beyond melanoma, the Swiss drugmaker told the American Society of Clinical Oncology's conference in Chicago on Tuesday. Novartis's Tafinlar and Mekinist combination shrank tumors in 63 percent of the trial's 57 people with BRAF V600E-mutation positive non-small cell lung cancer who had failed on chemotherapy, the company said, citing a Phase II study.